Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) Celecoxib is indicated 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA. 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA. 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older. 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS. 1.5 Acute Pain For the management of acute pain in adults. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 23, 2015 | Original application | Approved | None posted |
| Feb 26, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 1, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 20, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 20, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 15, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 23, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters